5.4% target lesion failure at 12 months. 0.4% stent thrombosis at 24 months. 0% late stent thrombosis at 12 months. EluNIR was found non-inferior to Resolute in a broad, less selected ‘more comers’ population.
Dr. Kandzari on the EluNIR eDES clinical program - Video
Watch Dr. David Kandzari of the Piedmont Heart Institute as he reviews the 1 year outcomes of two randomized trials on EluNIR, Medinol's elastomeric Drug Eluting Stent